Journal ArticleDOI
Use of leucocyte‐poor blood components and HLA‐matched‐platelet donors to prevent HLA alloimmunization
Reads0
Chats0
TLDR
Improved methods of removing leucocytes from blood components appear to offer the best approach for minimizing HLA alloimmunization, as the provision of HLA‐matched platelet donors for prophylactic platelet support of all patients is not feasible.Abstract:
Recent studies have shown that the incidence of alloimmunization due to repeated platelet transfusions from random donors may be reduced by the use of leucocyte-poor blood components. These results were confirmed by this study, where 16% of patients with acute leukaemia undergoing initial chemotherapy and receiving leucocyte-poor blood components developed lymphocytotoxic antibodies, compared with 48% of patients in a control group receiving standard (non-leucocyte-depleted) blood components. In a third group, who received leucocyte-poor blood components and HLA-matched platelets, none of the patients developed lymphocytotoxic antibodies. There was a low incidence of platelet-specific antibodies (8%) but no difference between the three groups. Improved methods of removing leucocytes from blood components appear to offer the best approach for minimizing HLA alloimmunization, as the provision of HLA-matched platelet donors for prophylactic platelet support of all patients is not feasible.read more
Citations
More filters
Journal ArticleDOI
Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
Charles A. Schiffer,Kenneth C. Anderson,Charles L. Bennett,Steven L. Bernstein,Linda S. Elting,Miriam Goldsmith,Michael Goldstein,Heather Hume,Jeffery J. McCullough,Rosemary E. McIntyre,Bayard L. Powell,John M. Rainey,Scott D. Rowley,Paolo Rebulla,Michael B. Troner,Alton H. Wagnon +15 more
TL;DR: The possible consequences of different approaches to the use of platelet transfusion were considered in evaluating a preference for one or another technique producing similar outcomes and cost alone was not a determining factor.
Journal ArticleDOI
Biologic effects of leukocytes present in transfused cellular blood products
TL;DR: There is increasing pressure from various sources for the reduction of the leukocyte content in allogeneic blood components to minimize the occurrence of their adverse effects and to define the optimal conditions required for the preparation of blood components ultimately destined for clinical use.
Journal ArticleDOI
Transfusion-associated graft-versus-host disease.
Journal ArticleDOI
Platelet transfusion refractoriness.
Eldad A. Hod,Joseph E. Schwartz +1 more
TL;DR: The aetiology, diagnosis, and management of refractoriness to platelet transfusion, a complicated problem for both the treating physicians and the transfusion services supporting these patients, is discussed.
Journal ArticleDOI
Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients : Frequent long-term microchimerism in severe trauma patients
TL;DR: A better understanding of factors determining clearance versus chimerism of transfused leukocytes is critical to prevention of alloimmunization and transfusion-induced graft-versus-host disease, and, potentially, to induction of tolerance for transplantation.
References
More filters
Journal ArticleDOI
A simple immunofluorescence test for the detection of platelet antibodies.
A. E. G. K. Von Dem Borne,F. W. A. Verheugt,F. Oosterhof,E von Riesz,A B de la Rivière,C. P. Engelfriet +5 more
TL;DR: By using PFA‐fixed platelets, a simple method for the detection of platelet antibodies, the platelet suspension immunofluorescence test (PSIFT) was developed.
Journal ArticleDOI
Differential function of major histocompatibility complex antigens in T-lymphocyte activation.
TL;DR: The antigenic systems of the major histocompatibility complex can be subdivided into thoseWhich are serologically detectable and those which are detected in tests with mixed lymphocytes.
Journal Article
Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
Eernisse Jg,Brand A +1 more
TL;DR: From January 1972 to July 1974, 28 patients with bone marrow depression due to aplastic anemia or cytostatic treatment, were transfused with packed cells and platelet concentrates, both containing 10-20% of the amount of leukocytes present in whole blood, and 26 became refractory to random platelets.
Journal ArticleDOI
A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia
Charles A. Schiffer,Janice P. Dutcher,Joseph Aisner,Donna E. Hogge,Peter H. Wiernik,James P. Reilly +5 more
TL;DR: WBC-depleted platelets should not be utilized to prevent alloimmunization in patients with leukemia because of the significant loss of platelets with WBC depletion, the expense and difficulty of providing WBC-poor RBC, the absence of impact on the need for HLA-matched platelets during induction, and the small potential benefit from this approach.
Journal ArticleDOI
The natural history of alloimmunization to platelets
J E Howard,H A Perkins +1 more
TL;DR: In the most heavily immunized patients, the presence of antibody correlated with poor increments of platelets after transfusion, and patients with prior exposure to HLA antigens are more likely to have antibodies resulting in poor platelet survival.
Related Papers (5)
Prevention of refractoriness and HLA-alloimmunization using filtered blood products.
Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components.
Eernisse Jg,Brand A +1 more